Characteristics of responders to atropine 0.01% as treatment in Asian myopic children.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 05 2022
05 05 2022
Historique:
received:
16
01
2022
accepted:
15
04
2022
entrez:
5
5
2022
pubmed:
6
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
Recently, low-concentration atropine (0.01%) has gained increased attention in controlling myopia progression with satisfying effects and minimal side effects. However, studies concerning responders to 0.01% atropine are limited. This retrospective observational cohort study aimed to determine the responder characteristics of 0.01% atropine in Asian children. One hundred forty children (aged between 3 and 15 years) receiving 0.01% atropine were analyzed for the factors influencing annual spherical equivalent changes (SE). The mean age was 9.13 (2.6) years, the mean baseline SE was - 1.56 (1.52) diopters (D), and the mean annual SE change was - 0.52 (0.49) D. A 58.63% responder rate (146/249) of myopic control was achieved with 0.01% atropine in our entire cohort under the criteria of less than 0.5 D of myopic progression annually. The subjects were stratified into 4 subgroups based on a cut-off point of baseline SE of - 1.5 D and baseline age of 9 years. The responder rate differed significantly with the highest being the youngest with the lowest myopia subgroups. Our results demonstrated that children with myopia better than - 1.5 D and younger than 9 years had the highest potential to achieve successful myopic control under 0.01% atropine therapy.
Identifiants
pubmed: 35513480
doi: 10.1038/s41598-022-10978-3
pii: 10.1038/s41598-022-10978-3
pmc: PMC9072680
doi:
Substances chimiques
Mydriatics
0
Ophthalmic Solutions
0
Atropine
7C0697DR9I
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7380Informations de copyright
© 2022. The Author(s).
Références
Prog Retin Eye Res. 2016 May;52:156-87
pubmed: 26769165
Ophthalmology. 2019 Jan;126(1):113-124
pubmed: 30514630
J Ocul Pharmacol Ther. 2015 Nov;31(9):541-5
pubmed: 26218150
J Ocul Pharmacol Ther. 2011 Oct;27(5):461-6
pubmed: 21815829
Optom Vis Sci. 2013 Dec;90(12):1467-72
pubmed: 24076540
Prog Retin Eye Res. 2018 Jan;62:134-149
pubmed: 28951126
Lancet. 2012 May 5;379(9827):1739-48
pubmed: 22559900
Ann Acad Med Singap. 2004 Jan;33(1):27-33
pubmed: 15008558
Nat Rev Dis Primers. 2020 Dec 17;6(1):99
pubmed: 33328468
Ophthalmology. 2021 Sep;128(9):1367-1369
pubmed: 33545170
Front Pharmacol. 2020 Sep 09;11:01081
pubmed: 33013354
Ophthalmology. 2016 Feb;123(2):391-399
pubmed: 26271839
Ophthalmology. 2006 Dec;113(12):2285-91
pubmed: 16996612
Br J Ophthalmol. 2020 Nov;104(11):1535-1541
pubmed: 32086237
Arch Ophthalmol. 2009 Dec;127(12):1632-9
pubmed: 20008719
Ophthalmology. 2012 Feb;119(2):347-54
pubmed: 21963266
Arch Soc Esp Oftalmol (Engl Ed). 2018 Apr;93(4):182-185
pubmed: 29398233
Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):49
pubmed: 32347918
J Ocul Pharmacol Ther. 2010 Aug;26(4):341-5
pubmed: 20698798
JAMA Ophthalmol. 2020 Nov 1;138(11):1178-1184
pubmed: 33001210
J Ophthalmol. 2020 Nov 4;2020:4395278
pubmed: 33489329
JAMA Ophthalmol. 2017 Jun 1;135(6):624-630
pubmed: 28494063
Jpn J Ophthalmol. 2021 May;65(3):315-325
pubmed: 33586090
Ophthalmol Ther. 2019 Dec;8(4):589-598
pubmed: 31602553
Ophthalmology. 2016 Apr;123(4):697-708
pubmed: 26826749
Graefes Arch Clin Exp Ophthalmol. 2018 Dec;256(12):2457-2466
pubmed: 30074069
Ophthalmology. 2020 Jul;127(7):910-919
pubmed: 32019700
Int J Ophthalmol. 2018 Oct 18;11(10):1657-1662
pubmed: 30364238
Am J Ophthalmol. 2014 Feb;157(2):451-457.e1
pubmed: 24315293
Ophthalmol Ther. 2019 Sep;8(3):427-433
pubmed: 31190219
Ophthalmic Epidemiol. 2007 Jul-Aug;14(4):230-7
pubmed: 17896302
Prog Retin Eye Res. 2021 Jul;83:100923
pubmed: 33253901
Am J Ophthalmol. 2015 May;159(5):945-9
pubmed: 25640408
Ophthalmology. 2016 May;123(5):1036-42
pubmed: 26875007
Cochrane Database Syst Rev. 2020 Jan 13;1:CD004916
pubmed: 31930781
Sci Rep. 2021 Nov 5;11(1):21748
pubmed: 34741059
Ophthalmology. 2021 Aug;128(8):1180-1187
pubmed: 33422558
Acta Ophthalmol. 2019 Dec;97(8):e1136-e1140
pubmed: 31197953